Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of ABI-H0731 in Patients With Chronic Hepatitis B

NCT03109730 is registered in ClinicalTrials.gov with Assembly Biosciences as lead sponsor.

NCT NCT03109730
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03109730 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of ABI-H0731 in Patients With Chronic Hepatitis B
Lead sponsor
Assembly Biosciences
Phase
Phase 1/2
Overall status
Completed
Start date
June 15, 2017
Completion date
June 12, 2018
Enrollment
38 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b